EA201692016A1 - Оптимальное дозирование конъюгата cd19-антитела с лекарственным средством - Google Patents

Оптимальное дозирование конъюгата cd19-антитела с лекарственным средством

Info

Publication number
EA201692016A1
EA201692016A1 EA201692016A EA201692016A EA201692016A1 EA 201692016 A1 EA201692016 A1 EA 201692016A1 EA 201692016 A EA201692016 A EA 201692016A EA 201692016 A EA201692016 A EA 201692016A EA 201692016 A1 EA201692016 A1 EA 201692016A1
Authority
EA
Eurasian Patent Office
Prior art keywords
medicine
antibody conjugate
optimal dosing
dosing
antibody
Prior art date
Application number
EA201692016A
Other languages
English (en)
Inventor
Байтэн Чжао
Тина Альбертсон
Тае Хань
Original Assignee
Сиэтл Дженетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэтл Дженетикс, Инк. filed Critical Сиэтл Дженетикс, Инк.
Publication of EA201692016A1 publication Critical patent/EA201692016A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Раскрываются способы оптимального дозирования конъюгатов CD19-антитела с лекарственным средством.
EA201692016A 2014-04-08 2015-04-07 Оптимальное дозирование конъюгата cd19-антитела с лекарственным средством EA201692016A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461976790P 2014-04-08 2014-04-08
PCT/US2015/024732 WO2015157297A1 (en) 2014-04-08 2015-04-07 Optimal dosing of a cd19-antibody drug conjugate

Publications (1)

Publication Number Publication Date
EA201692016A1 true EA201692016A1 (ru) 2017-01-30

Family

ID=54288332

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692016A EA201692016A1 (ru) 2014-04-08 2015-04-07 Оптимальное дозирование конъюгата cd19-антитела с лекарственным средством

Country Status (12)

Country Link
US (1) US20170182178A1 (ru)
EP (1) EP3129052B1 (ru)
JP (1) JP2017512801A (ru)
KR (1) KR20160141727A (ru)
CN (1) CN106170300A (ru)
AU (1) AU2015244004A1 (ru)
CA (1) CA2941154A1 (ru)
EA (1) EA201692016A1 (ru)
IL (1) IL247526A0 (ru)
MX (1) MX2016012258A (ru)
SG (1) SG11201607133QA (ru)
WO (1) WO2015157297A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45625A (fr) * 2016-07-08 2019-05-15 Genmab As Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl
UA127900C2 (uk) * 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
CN109069584A (zh) * 2017-06-29 2018-12-21 成都华创生物技术有限公司 一种trail类蛋白持续抑制肿瘤细胞生长的给药方法
EP3728330A4 (en) * 2017-12-23 2021-12-08 Uwell Biopharma Inc. PHARMACEUTICAL COMPOSITION OF CHEMICAL RECEPTOR AND ASSOCIATED PROCESS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ583292A (en) * 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP2211904B1 (en) * 2007-10-19 2016-08-17 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
NO2582728T3 (ru) * 2010-06-15 2018-01-20
EP3581206A1 (en) * 2010-10-22 2019-12-18 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the p13k-akt mtor pathway
AU2012258637B2 (en) * 2011-05-24 2017-07-20 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses

Also Published As

Publication number Publication date
JP2017512801A (ja) 2017-05-25
IL247526A0 (en) 2016-11-30
US20170182178A1 (en) 2017-06-29
SG11201607133QA (en) 2016-09-29
MX2016012258A (es) 2017-01-06
CN106170300A (zh) 2016-11-30
EP3129052A4 (en) 2017-11-15
WO2015157297A1 (en) 2015-10-15
KR20160141727A (ko) 2016-12-09
CA2941154A1 (en) 2015-10-15
EP3129052A1 (en) 2017-02-15
AU2015244004A1 (en) 2016-09-15
EP3129052B1 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
FR21C1030I2 (fr) Conjugué anticorps anti-her2-médicament
HK1232123A1 (zh) 親水性抗體-藥物偶聯物
IL252015A0 (en) Antibody drug conjugates
IL247936A0 (en) Antibodies against egfr and drug antibody conjugates
IL250319A0 (en) Stabilizing binders for use in drug-antibody conjugates
IL250189A0 (en) Anti–cdh6 antibody drug conjugates
IL291073A (en) Drug conjugates of anti-egfr antibodies
IL251938A0 (en) Antibodies against CS1 and antibody-drug conjugates
DK3134127T3 (da) Antistoflægemiddelkonjugater med høj lægemiddelladning
CL2015002246A1 (es) Conjugados de anticuerpos drogas.
IL267834A (en) Conjugates of drug and antibody against CCR7
IL259651A (en) Conjugations between an antibody to a specific her2 site and a drug
SG11201702786RA (en) Glycoengineered antibody drug conjugates
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
EP3250238A4 (en) Antibody drug conjugates
EP3253212A4 (en) Antibody drug conjugates
DK3145984T3 (da) Terapeutiske konjugater med sulfaterede dendrimerer til intracellulær målretning
LU92659B1 (en) Glycooptimized antibody drug conjugates
EA201692016A1 (ru) Оптимальное дозирование конъюгата cd19-антитела с лекарственным средством
GB201418984D0 (en) Novel drug conjugates